Department of Endocrinology, First Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
Department of Endocrinology, First Affiliated Hospital of Harbin Medical University, Harbin 150001, China.
Pharmacol Res. 2020 Sep;159:104924. doi: 10.1016/j.phrs.2020.104924. Epub 2020 May 25.
Diabetic retinopathy (DR) is a serious condition that can cause blindness in diabetic patients. It is a neurovascular disease, but the pathogenesis leading to the onset of this disease is still not completely understood. However, hypoxia with subsequent neovascularization is a characteristic phenomenon observed with DR. Cellular response to hypoxia is mediated by the transcriptional regulator hypoxia-inducible factor (HIF). Long-term research has shown that one isotype of HIF, HIF-1α, may play a pivotal role under hypoxic conditions, and an increasing number of studies have shown that HIF-1α and its target genes contribute to retinal neovascularization. Therefore, targeting HIF-1α may lead to more effective DR treatments. This review describes the possible mechanisms of HIF-1α in neovascularization of DR. Furthermore, various inhibitors of HIF-1α that may have viable potential in the treatment of DR are also discussed.
糖尿病性视网膜病变（DR）是一种可导致糖尿病患者失明的严重疾病。它是一种神经血管疾病，但导致该疾病发生的确切机制尚不完全清楚。然而，缺氧随后导致新生血管形成是 DR 观察到的一个特征现象。细胞对缺氧的反应由转录调节因子缺氧诱导因子（HIF）介导。长期研究表明，HIF 的一种同型物 HIF-1α，在缺氧条件下可能发挥关键作用，越来越多的研究表明 HIF-1α及其靶基因有助于视网膜新生血管形成。因此，针对 HIF-1α 可能会导致更有效的 DR 治疗。本文综述了 HIF-1α 在 DR 新生血管形成中的可能机制。此外，还讨论了可能具有 DR 治疗潜力的各种 HIF-1α 抑制剂。
